Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fattal

Showing results (21-30 of 793) with videos related to

Pageof 80
Sort By:
British Journal of Pharmacology|April 16, 2009
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNAElias Fattal, Gillian Barratt
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 1, 2012
Liposomes for intravitreal drug delivery: a state of the artAmélie Bochot, Elias Fattal
Journal of Nanoscience and Nanotechnology|October 20, 2006
Design and characterisation of poly(lactide-co-glycolide) small particulate systems for the delivery of immunostimulant CpG oligonucleotideMonjed Shakweh, Elias Fattal
Harefuah|August 1, 1991
[Morbidity in primary care clinics of 29 kibbutzim--prospective study]P Yekutiel, B Fattal
International Journal of Pharmaceutics|July 16, 2008
State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriersElias Fattal, Amélie Bochot
Advanced Drug Delivery Reviews|November 14, 2006
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNAElias Fattal, Amélie Bochot
Archivos De La Sociedad Espanola De Oftalmologia|February 2, 2006
Antisense oligonucleotides, aptamers and SiRNA: promises for the treatment of ocular diseasesE Fattal, A Bochot
Harefuah|May 1, 1991
[Morbidity among kibbutz children determined by health interview]O Tadmor, B Fattal
International Journal of Technology Assessment in Health Care|October 3, 2008
Health technology assessment use and dissemination by patient and consumer groups: why and how?Julie Fattal, Pascale Lehoux
Harefuah|November 1, 1992
[Congenital cytomegalic virus infection]A Valevski-Fattal, S Harel
Pageof 80

Showing results (21-30 of 793) with videos related to

Sort By:
Pageof 80
British Journal of Pharmacology|April 16, 2009
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNAElias Fattal, Gillian Barratt
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 1, 2012
Liposomes for intravitreal drug delivery: a state of the artAmélie Bochot, Elias Fattal
Journal of Nanoscience and Nanotechnology|October 20, 2006
Design and characterisation of poly(lactide-co-glycolide) small particulate systems for the delivery of immunostimulant CpG oligonucleotideMonjed Shakweh, Elias Fattal
Harefuah|August 1, 1991
[Morbidity in primary care clinics of 29 kibbutzim--prospective study]P Yekutiel, B Fattal
International Journal of Pharmaceutics|July 16, 2008
State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriersElias Fattal, Amélie Bochot
Advanced Drug Delivery Reviews|November 14, 2006
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNAElias Fattal, Amélie Bochot
Archivos De La Sociedad Espanola De Oftalmologia|February 2, 2006
Antisense oligonucleotides, aptamers and SiRNA: promises for the treatment of ocular diseasesE Fattal, A Bochot
Harefuah|May 1, 1991
[Morbidity among kibbutz children determined by health interview]O Tadmor, B Fattal
International Journal of Technology Assessment in Health Care|October 3, 2008
Health technology assessment use and dissemination by patient and consumer groups: why and how?Julie Fattal, Pascale Lehoux
Harefuah|November 1, 1992
[Congenital cytomegalic virus infection]A Valevski-Fattal, S Harel
Pageof 80